CRL4 (CRBN) ユビキチンリガゼによるレナリドミド誘発CK1α分解の構造的基礎
Georg Petzold1,2, Eric S Fischer1,2, Nicolas H Thomä1,2
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland.
Nature
|February 25, 2016
まとめ
レナリドミドは免疫調節薬 (IMiD) で,CRL4 (CRBN) E3ユビキチンリガスを再利用して,CK1αのようなタンパク質を分解する. このメカニズムは,レナリドミドの
科学分野:
- 構造生物学
- 分子薬理学
- ガン治療
背景:
- レナリドミドのような免疫調節薬 (IMiDs) は,CRL4 (CRBN) E3ユビキチンリガゼを標的にして,血液性悪性腫瘍を治療する.
- IMiDsはCRBNと結合し,基板特異性を変化させ,特定のタンパク質の分解につながります.
研究 の 目的:
- CRL4 ((CRBN)) によってレナリドミド誘発されたタンパク質の分解の構造的基礎を解明する.
- レナリドミドがCK1αとIKZF1をどのように分解するかを理解する.
主な方法:
- レナリドミドとCK1αに結合するDDB1-CRBNの2.45 Å構造を決定するX線結晶学.
- IMiDsに対するタンパク質結合の依存性を評価する生化学的測定法.
主要な成果:
- 結晶構造は,CRBNとレナリドミドがCK1αの結合インターフェースを形成していることを示している.
- CK1αとIKZF1がCRL4とCRBNと結合することは,IMiDの存在に厳密に依存しています.
- CK1αとIKZF1は,CRBNと同様の結合モードを使用しています.
結論:
- レナリドミドのメカニズムは,CRL4 ((CRBN) を再利用して,共有結合方式を通じてCK1αとIKZF1を分解する.
- これは,骨髄不全症候群の治療におけるレナリドミドの有効性のメカニズム的な説明を提供する.
- 小分子誘発のタンパク質相互作用は,標的型タンパク質分解薬の開発に有望な機会を提供します.
関連する概念動画
Regulated Protein Degradation
9.2K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.2K
Regulated Protein Degradation
3.3K
3.3K
Anaphase Promoting Complex
3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Covalently Linked Protein Regulators
9.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
9.9K
Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Export of Misfolded Proteins out of the ER
5.5K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.5K


